Your browser is no longer supported. Please, upgrade your browser.
Biohaven Pharmaceutical Holding Company Ltd.
Index- P/E- EPS (ttm)-14.40 Insider Own3.90% Shs Outstand65.11M Perf Week-1.01%
Market Cap8.99B Forward P/E- EPS next Y-7.42 Insider Trans0.00% Shs Float56.23M Perf Month8.05%
Income-888.50M PEG- EPS next Q-2.57 Inst Own95.31% Short Float6.37% Perf Quarter39.35%
Sales189.50M P/S47.45 EPS this Y-19.70% Inst Trans20.76% Short Ratio6.69 Perf Half Y101.17%
Book/sh-6.97 P/B- EPS next Y41.60% ROA-107.10% Target Price134.36 Perf Year114.04%
Cash/sh5.52 P/C24.56 EPS next 5Y- ROE266.70% 52W Range60.20 - 139.66 Perf YTD58.15%
Dividend- P/FCF- EPS past 5Y- ROI-198.10% 52W High-2.94% Beta1.02
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin76.60% 52W Low125.17% ATR4.47
Employees825 Current Ratio1.70 Sales Q/Q857.70% Oper. Margin- RSI (14)58.54 Volatility2.88% 3.37%
OptionableYes Debt/Eq- EPS Q/Q-5.00% Profit Margin- Rel Volume0.40 Prev Close134.01
ShortableYes LT Debt/Eq- EarningsAug 09 BMO Payout- Avg Volume536.16K Price135.55
Recom1.80 SMA201.78% SMA507.51% SMA20043.92% Volume216,603 Change1.15%
Aug-10-21Downgrade UBS Buy → Neutral $108 → $109
Aug-03-21Reiterated Canaccord Genuity Buy $101 → $150
Mar-11-21Initiated UBS Buy $108
Dec-15-20Initiated H.C. Wainwright Buy $121
Apr-17-20Initiated Cowen Outperform $45
Feb-10-20Downgrade Oppenheimer Outperform → Perform
Feb-06-20Initiated Mizuho Buy
Nov-22-19Initiated Wedbush Outperform
Jun-25-19Reiterated Canaccord Genuity Buy $89 → $84
May-06-19Initiated Goldman Buy $92
Apr-09-19Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-04-19Reiterated Needham Buy $48 → $56
Jul-03-18Reiterated Needham Buy $36 → $48
Jul-02-18Reiterated Needham Buy $36 → $48
Apr-05-18Downgrade Barclays Overweight → Equal Weight $30 → $25
Feb-22-18Reiterated Canaccord Genuity Buy $30 → $39
Dec-15-17Initiated Canaccord Genuity Buy $30
Oct-03-17Reiterated Needham Buy $43 → $36
Sep-10-21 10:51AM  
Sep-09-21 07:30AM  
Sep-08-21 11:30AM  
Aug-27-21 08:42AM  
Aug-09-21 12:13PM  
Aug-02-21 03:01PM  
Jul-29-21 07:30AM  
Jul-28-21 07:30AM  
Jul-23-21 01:38AM  
Jul-17-21 06:22AM  
Jul-16-21 07:30PM  
Jul-12-21 08:30AM  
Jul-09-21 01:31AM  
Jul-08-21 11:23AM  
Jul-07-21 04:09PM  
Jul-06-21 09:43AM  
Jun-23-21 03:00AM  
Jun-17-21 04:01PM  
Jun-15-21 02:31PM  
Jun-09-21 11:30AM  
Jun-08-21 12:35PM  
Jun-03-21 07:30AM  
May-28-21 10:41AM  
May-27-21 04:15PM  
May-24-21 09:06AM  
May-14-21 07:30AM  
May-13-21 01:16AM  
May-11-21 11:08AM  
May-10-21 04:08PM  
May-03-21 03:01PM  
Apr-30-21 01:34PM  
Apr-28-21 07:30AM  
Apr-13-21 07:30AM  
Apr-08-21 09:22AM  
Apr-07-21 04:10PM  
Apr-06-21 07:30AM  
Apr-02-21 01:40AM  
Mar-29-21 03:01PM  
Mar-28-21 11:42AM  
Mar-23-21 03:56AM  
Mar-15-21 10:16PM  
Mar-12-21 11:29AM  
Mar-11-21 11:20AM  
Mar-10-21 06:22PM  
Mar-04-21 03:57PM  
Mar-02-21 09:56AM  
Mar-01-21 04:00PM  
Feb-23-21 06:40PM  
Feb-22-21 07:30AM  
Feb-08-21 07:30AM  
Jan-25-21 07:30AM  
Jan-20-21 12:13PM  
Jan-19-21 04:12PM  
Jan-18-21 10:10AM  
Jan-07-21 07:30AM  
Jan-05-21 10:00AM  
Jan-04-21 07:30AM  
Dec-30-20 08:49AM  
Dec-21-20 05:18PM  
Dec-16-20 07:30AM  
Dec-07-20 10:00AM  
Dec-03-20 12:33PM  
Dec-02-20 10:05AM  
Nov-30-20 08:00AM  
Nov-22-20 09:32PM  
Nov-19-20 09:51AM  
Nov-16-20 09:00AM  
Nov-11-20 04:30PM  
Nov-10-20 10:39AM  
Nov-09-20 08:32AM  
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHILDS JOHN WDirectorMar 17Buy76.0013,157999,9322,545,801Mar 17 05:13 PM
CHILDS JOHN WDirectorMar 02Buy85.1410,000851,3702,532,644Mar 03 09:22 PM
Coric VladChief Executive OfficerJan 06Option Exercise0.0012,500025,211Jan 08 08:48 PM
Conway CharlesChief Scientific OfficerJan 06Option Exercise0.003,750011,759Jan 08 08:48 PM
Engelhart JamesChief Financial OfficerJan 06Option Exercise0.003,750010,958Jan 08 08:48 PM
Gentile KimberlySVP, Clinical OperationsJan 06Option Exercise0.003,75009,438Jan 08 08:48 PM
Stock ElyseChief Medical OfficerJan 06Option Exercise0.001,25002,187Jan 08 08:49 PM
Stock ElyseChief Medical OfficerJan 06Option Exercise0.003,75007,438Jan 08 08:49 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseJan 06Option Exercise0.005,00009,251Jan 08 08:49 PM
Tilton JohnChief Commercial OfficerJan 06Option Exercise0.001,25003,151Jan 08 08:49 PM
Conway CharlesChief Scientific OfficerNov 25Option Exercise0.003,00008,639Nov 27 09:47 PM
Coric VladChief Executive OfficerNov 25Option Exercise0.0010,950016,935Nov 27 09:47 PM
Engelhart JamesChief Financial OfficerNov 25Option Exercise0.003,70008,222Nov 27 09:47 PM
Gentile KimberlySVP, Clinical OperationsNov 25Option Exercise0.003,75007,389Nov 27 09:48 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseNov 25Option Exercise0.003,00004,755Nov 27 09:48 PM
Stock ElyseChief Medical OfficerNov 25Option Exercise0.003,37505,219Nov 27 09:48 PM
Tilton JohnChief Commercial OfficerNov 25Option Exercise0.001,25002,020Nov 27 09:48 PM
CHILDS JOHN WDirectorNov 23Buy89.555,000447,7372,516,938Nov 23 08:40 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseNov 02Option Exercise50.7230,0001,521,60031,755Nov 04 08:31 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseNov 02Sale76.2230,0002,286,6761,755Nov 04 08:31 PM
Bailey GregoryDirectorOct 23Sale78.9110,403820,8662,545,658Oct 23 09:25 PM
Bailey GregoryDirectorOct 22Sale79.4724,5661,952,3522,556,061Oct 23 09:25 PM
Bailey GregoryDirectorOct 19Sale78.984,554359,6552,580,627Oct 21 09:24 PM
Bailey GregoryDirectorOct 16Sale78.883,748295,6382,585,181Oct 21 09:24 PM
Bailey GregoryDirectorOct 12Sale78.876,729530,7402,588,929Oct 14 09:31 PM
Gentile KimberlySVP, Clinical OperationsOct 08Option Exercise9.2923,500218,31527,139Oct 09 06:42 PM
Gentile KimberlySVP, Clinical OperationsOct 08Sale76.3423,5001,794,0823,639Oct 09 06:42 PM